Company’s focus on advancing first-in-class oral degraders with biologics-like activity to address areas of significant patient need and market potential STAT6 oral degrader KT-621, with ...
WALTHAM, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals, a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, today announced that the U.S. Food and Drug ...
"How do we engage with people that we are supposed to be serving?" Dr. Frances Lund, director of the Immunology Institute, said at the Aspen Ideas Health in Aspen, CO on June 25, 2025. She was invited ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback